Instylla Logo

Materializing Solutions

Instylla delivers next-generation liquid embolics for interventional radiology, with initial clinical applications in interventional oncology and peripheral hemostasis.

LatesT news

Instylla Completes Enrollment of Landmark Hypervascular Tumor Pivotal Study

May 14, 2024

Clinical investigators achieve significant milestone by enrolling 150 patients with hypervascular tumors in pivotal randomized study. BEDFORD, Mass., – May 14, 2024 – Instylla, Inc., a privately held clinical-stage company focused on developing liquid embolics for peripheral vascular embolotherapy, today announced the completion of patient enrollment in the ongoing Instylla HES Hypervascular Tumor Pivotal Study. […]

Read More